TMEM170B Activators
TMEM170B, identified as a transmembrane protein residing in the plasma membrane, plays a pivotal role in the intricate regulation of the canonical Wnt signaling pathway. The primary function of TMEM170B lies in its capacity to negatively modulate Wnt signaling, a pathway crucial for cellular processes such as development, differentiation, and homeostasis. By residing at the plasma membrane, TMEM170B is strategically positioned to interfere with the activation of Wnt signaling at an early stage.
Activation of TMEM170B is achieved through a variety of mechanisms involving specific chemical interventions. These chemicals either directly activate TMEM170B by inhibiting key components of the Wnt pathway, such as GSK-3 or tankyrase, or indirectly enhance TMEM170B activity by disrupting various points within the canonical Wnt signaling cascade. For instance, the inhibition of Wnt ligand secretion or interference with β-catenin transcriptional activity facilitates TMEM170B's negative regulation of Wnt signaling. The intricate dance of these chemical activators underscores the versatility of TMEM170B in fine-tuning the canonical Wnt pathway, ensuring the precise control of downstream cellular responses associated with Wnt activation. This negative regulatory role of TMEM170B in Wnt signaling highlights its significance in maintaining cellular homeostasis and preventing aberrant cellular behaviors associated with unrestrained Wnt pathway activity. The delicate balance orchestrated by TMEM170B exemplifies its role as a sentinel at the plasma membrane, strategically guarding against unwarranted Wnt signaling activation and contributing to the overall precision of cellular responses in a variety of biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3β, indirectly activating TMEM170B by disrupting the canonical Wnt signaling pathway. This intervention stabilizes β-catenin, preventing its degradation, and subsequently promotes TMEM170B's negative regulation of Wnt signaling. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Directly activates TMEM170B by inhibiting Wnt/β-catenin signaling. Niclosamide disrupts the stability and nuclear translocation of β-catenin, relieving the inhibitory effect on TMEM170B and allowing for enhanced negative regulation of the canonical Wnt pathway. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Indirectly stimulates TMEM170B through inhibition of the Wnt/β-catenin pathway. Curcumin impedes β-catenin translocation to the nucleus, augmenting TMEM170B's ability to negatively regulate Wnt signaling and attenuate downstream cellular responses associated with Wnt activation. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
Enhances TMEM170B activity by inhibiting tankyrase, leading to the stabilization of AXIN1. This stabilization promotes the formation of the destruction complex, which facilitates TMEM170B's negative regulation of the canonical Wnt signaling pathway. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
Directly activates TMEM170B by inhibiting GSK-3, a key player in the Wnt signaling pathway. Inhibition of GSK-3 prevents phosphorylation of β-catenin, allowing TMEM170B to effectively down-regulate Wnt signaling and its downstream effects on cellular processes. | ||||||
NSC 668036 | 144678-63-7 | sc-507412 | 5 mg | $175.00 | ||
Directly activates TMEM170B by inhibiting the nuclear translocation of β-catenin. NSC668036 interferes with the canonical Wnt pathway, allowing TMEM170B to exert its inhibitory effect on Wnt signaling and regulate cellular responses associated with the pathway's activation. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $96.00 $292.00 | 27 | |
Inhibits PORCN, indirectly activating TMEM170B by blocking Wnt ligand secretion. This intervention limits the availability of Wnt ligands, preventing their interaction with receptors and allowing TMEM170B to negatively regulate canonical Wnt signaling more effectively. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
Inhibits PORCN, indirectly enhancing TMEM170B activation by suppressing Wnt ligand secretion. LGK974 limits Wnt ligand availability, facilitating TMEM170B's negative regulation of the canonical Wnt signaling pathway and attenuating downstream effects associated with Wnt activation. | ||||||
PRI-724 | 1422253-38-0 | sc-507535 | 25 mg | $260.00 | ||
Disrupts the interaction between β-catenin and CBP, indirectly activating TMEM170B. PRI-724 inhibits the transcriptional activity of β-catenin, promoting TMEM170B's negative regulation of Wnt signaling and modulating the downstream cellular responses associated with canonical Wnt pathway activation. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $182.00 $374.00 | 7 | |
Inhibits the Wnt/β-catenin and PPARγ pathways, indirectly enhancing TMEM170B activity. FH535 interferes with both pathways, allowing TMEM170B to exert its negative regulation on Wnt signaling more effectively and modulating cellular responses associated with the canonical pathway. | ||||||